VALMID
LOE Approachingethinamate
NDAORALCAPSULE
Approved
Mar 1955
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VALMID (ethinamate) is an oral capsule sedative-hypnotic agent approved in 1955 for short-term management of insomnia and related sleep disorders. The drug functions as a central nervous system depressant, though its precise mechanism of action is not fully characterized in modern literature. It represents a legacy small-molecule therapeutic from the mid-20th century era of barbiturate and non-barbiturate sedatives.
LOE Approaching
Product approaching loss of exclusivity with minimal linked commercial opportunity; brand team likely in defensive/maintenance mode with reduced headcount.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VALMID offers minimal career growth opportunity; the product is in LOE/post-LOE phase with zero linked job openings and declining market relevance. Career prospects are limited to defensive regulatory, compliance, and medical information support roles rather than commercial expansion or innovation.
Regulatory Affairs SpecialistMedical Information Specialist
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.